Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD

NEXT STORY
Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market is Expected to Reach USD 5.07 Billion by 2026 : Fior Markets
PREV STORY
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bio-Path Holdings Reports Second Quarter 2016 Financial Results

HOUSTON, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company ...

author_avatar
NASDAQ Market News

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2018 Financial Results

Conference Call Scheduled for July 19, 2018 at 11:00 am EASTERNDUBLIN, Ireland, July 12, ...

author_avatar
NASDAQ Market News

Mesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumatology

NEW YORK and MELBOURNE, Australia, June 22, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) ...

author_avatar
NASDAQ Market News